NZ336980A - 1-(Benzofurazan or benzothiazdiazole) substituted carbonyl-piperidine, -thiomorpholine or -morpholine derivatives which enhance AMPA receptor activity - Google Patents

1-(Benzofurazan or benzothiazdiazole) substituted carbonyl-piperidine, -thiomorpholine or -morpholine derivatives which enhance AMPA receptor activity

Info

Publication number
NZ336980A
NZ336980A NZ336980A NZ33698098A NZ336980A NZ 336980 A NZ336980 A NZ 336980A NZ 336980 A NZ336980 A NZ 336980A NZ 33698098 A NZ33698098 A NZ 33698098A NZ 336980 A NZ336980 A NZ 336980A
Authority
NZ
New Zealand
Prior art keywords
independently
thiomorpholine
piperidine
ampa receptor
crr
Prior art date
Application number
NZ336980A
Other languages
English (en)
Inventor
Gary A Rogers
Christopher M Marrs
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NZ336980A publication Critical patent/NZ336980A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
NZ336980A 1997-02-13 1998-02-13 1-(Benzofurazan or benzothiazdiazole) substituted carbonyl-piperidine, -thiomorpholine or -morpholine derivatives which enhance AMPA receptor activity NZ336980A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses
PCT/US1998/002713 WO1998035950A1 (en) 1997-02-13 1998-02-13 Benzofurazan compounds which enhance ampa receptor activity

Publications (1)

Publication Number Publication Date
NZ336980A true NZ336980A (en) 2000-08-25

Family

ID=25177504

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336980A NZ336980A (en) 1997-02-13 1998-02-13 1-(Benzofurazan or benzothiazdiazole) substituted carbonyl-piperidine, -thiomorpholine or -morpholine derivatives which enhance AMPA receptor activity

Country Status (24)

Country Link
US (3) US6110935A (enExample)
EP (2) EP1428534B1 (enExample)
JP (1) JP4446023B2 (enExample)
KR (1) KR100544295B1 (enExample)
CN (1) CN1085206C (enExample)
AT (2) ATE326221T1 (enExample)
AU (1) AU737802C (enExample)
BR (1) BR9807333B1 (enExample)
CA (1) CA2279319C (enExample)
CZ (1) CZ299765B6 (enExample)
DE (2) DE69823803T2 (enExample)
DK (2) DK0960105T3 (enExample)
ES (2) ES2264078T3 (enExample)
GB (1) GB2325225B (enExample)
HU (1) HUP0002303A3 (enExample)
ID (1) ID22342A (enExample)
IL (1) IL131200A (enExample)
NO (1) NO318935B1 (enExample)
NZ (1) NZ336980A (enExample)
PL (1) PL199135B1 (enExample)
PT (2) PT960105E (enExample)
RU (1) RU2189984C2 (enExample)
TR (1) TR199901941T2 (enExample)
WO (1) WO1998035950A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
BRPI0406736A (pt) * 2003-01-13 2005-12-20 Cortex Pharma Inc Método de tratar declìnico cognitivo devido à privação de sono e estresse
JP4829791B2 (ja) * 2003-05-23 2011-12-07 バジリア ファルマスーチカ アーゲー フラザノベンゾイミダゾール
EP1715863B1 (en) * 2004-01-26 2012-05-09 Cortex Pharmaceuticals, Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
EP2061471A4 (en) * 2006-08-31 2012-02-01 Univ Alberta PROCESS FOR INHIBITING RESTRICTED DEPRESSION WITH POSITIVE ALLOSTER AMPA RECEPTOR MODULATORS
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101616592B (zh) * 2007-01-03 2013-06-05 瑟维尔实验室 用于提高谷氨酸能突触响应的3-取代的-[1,2,3]-苯并三嗪酮化合物
TW200911768A (en) * 2007-05-17 2009-03-16 Cortex Pharma Inc Di-substituted amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
WO2010087981A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
CA2829006A1 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1H-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
DK1156043T3 (da) * 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
ATE326221T1 (de) 2006-06-15
EP0960105A1 (en) 1999-12-01
AU6159998A (en) 1998-09-08
GB2325225A (en) 1998-11-18
NO993768L (no) 1999-09-23
WO1998035950A1 (en) 1998-08-20
CA2279319A1 (en) 1998-08-20
DK0960105T3 (da) 2004-08-30
DE69834590D1 (de) 2006-06-22
GB9809221D0 (enExample) 1998-07-01
EP1428534A1 (en) 2004-06-16
NO318935B1 (no) 2005-05-30
AU737802B2 (en) 2001-08-30
CA2279319C (en) 2008-08-05
DE69823803D1 (de) 2004-06-17
BR9807333B1 (pt) 2011-10-18
AU737802C (en) 2005-05-12
CZ279599A3 (cs) 2000-01-12
IL131200A0 (en) 2001-01-28
DK1428534T3 (da) 2006-06-12
GB2325225A8 (en) 1999-02-17
CZ299765B6 (cs) 2008-11-19
US6730677B2 (en) 2004-05-04
IL131200A (en) 2005-06-19
KR100544295B1 (ko) 2006-01-23
CN1085206C (zh) 2002-05-22
ID22342A (id) 1999-09-30
HUP0002303A3 (en) 2002-09-30
JP4446023B2 (ja) 2010-04-07
EP1428534B1 (en) 2006-05-17
US6313115B1 (en) 2001-11-06
CN1247534A (zh) 2000-03-15
NO993768D0 (no) 1999-08-04
RU2189984C2 (ru) 2002-09-27
ES2264078T3 (es) 2006-12-16
GB2325225B (en) 1999-03-03
BR9807333A (pt) 2000-04-18
JP2001512459A (ja) 2001-08-21
DE69823803T2 (de) 2005-04-14
US20020055508A1 (en) 2002-05-09
KR20000071082A (ko) 2000-11-25
PT1428534E (pt) 2006-07-31
TR199901941T2 (xx) 1999-12-21
PL335058A1 (en) 2000-03-27
HUP0002303A2 (hu) 2001-04-28
EP0960105B1 (en) 2004-05-12
ES2221152T3 (es) 2004-12-16
ATE266649T1 (de) 2004-05-15
PL199135B1 (pl) 2008-08-29
DE69834590T2 (de) 2007-04-26
US6110935A (en) 2000-08-29
PT960105E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
NZ336980A (en) 1-(Benzofurazan or benzothiazdiazole) substituted carbonyl-piperidine, -thiomorpholine or -morpholine derivatives which enhance AMPA receptor activity
TW360990B (en) Electroconversion cell
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
SE8201854L (sv) N-substituerade amino-aminosyror
CA2116967A1 (en) Antidepressants
IE801713L (en) N-(3-mercapto-2-alkyl-1-oxopropyl)-2,¹3-dihydro-1h-indole-2-carboxylic acids
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
CA2095444A1 (en) Fused pyrazine derivatives
ATE184194T1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)- homoserinlacton
PH20468A (en) Novel pharmaceutically active di-esters of 3,5-dicarboxy-4-substituted-pyridines and pyrans
DE3875073D1 (enExample)
DE69416501D1 (de) 2-propylvaleriansäure und 2-propylvalerian-säureamid-derivate und deren verwendung als antikonvulsive mittel
ES465384A1 (es) Procedimiento para la obtencion de ciclopentan-1-aminas
AP9801321A0 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-h-indole derivatives.
DE69830045D1 (de) Arylpiperidinopropanol und arylpiperazinopropanol derivate und die selbe enthaltende pharmazeutika
DK0434960T3 (da) Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter
CA2168937A1 (en) Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz[b,f]oxepines
MY131762A (en) Pharmaceutical compounds
ATE72242T1 (de) Benzothiazepin-derivate.
CA2064108A1 (en) Thiazolidinone and Oxazolidinone Derivatives, Their Preparation and Their Use as Vasodilators
AU4271389A (en) Phenylalkyl or phenylalkoxyethyl substituted piperazine derivatives
AU2971997A (en) Intermediates for oligonucleotide synthesis
TR200100214T2 (tr) Aerotrisin analogları, bunların hazırlanmaları ve kullanımları
MX9805061A (es) Preparacion estereoselectiva de derivados succinicos 2-substituidos.
TW360677B (en) HALS phosphoramides as stabilisers

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired